Pertussis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 2: | Line 2: | ||
{{CMG}}; {{AE}} {{ADI}} | {{CMG}}; {{AE}} {{ADI}} | ||
{{Pertussis}} | {{Pertussis}} | ||
==Overview== | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
'''Post exposure prophylaxis''' | '''Post exposure prophylaxis''' | ||
* Postexposure antibiotic prophylaxis is needed for individuals with close contact to a person with pertussis. | * Postexposure antibiotic prophylaxis is needed for individuals with close contact to a person with pertussis. | ||
* Administration of postexposure therapy to asymptomatic contacts of the infected patient within 21 days of onset of cough can prevent symptomatic infection. | * Administration of postexposure therapy to asymptomatic contacts of the infected patient within 21 days of onset of cough can prevent symptomatic infection.<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref> | ||
* The recommended antimicrobial agents for treatment or chemoprophylaxis of pertussis are [[azithromycin]], [[clarithromycin]] and [[erythromycin]]. [[Trimethoprim-sulfamethoxasole]] can also be used.<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref> | |||
===Infants=== | |||
====Age ≥1 Month==== | |||
* [[Erythromycin]], [[clarithromycin]], and [[azithromycin]] are preferred for the post exposure prophylaxis of pertussis in persons ≥1 month of age.<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref> | |||
* For persons ≥2 months of age, an alternative to [[macrolide]]s is [[trimethoprim-sulfamethoxazole]].<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref> | |||
====Age <1 Month==== | |||
* For infants <1 month of age, [[azithromycin]] is preferred for post exposure prophylaxis and treatment because [[azithromycin]] has not been associated with [[infantile hypertrophic pyloric stenosis]] (IHPS), whereas [[erythromycin]] has.<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref> | |||
==References== | ==References== | ||
Revision as of 17:28, 7 January 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
|
Pertussis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pertussis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Pertussis secondary prevention |
|
Risk calculators and risk factors for Pertussis secondary prevention |
Overview
Secondary Prevention
Post exposure prophylaxis
- Postexposure antibiotic prophylaxis is needed for individuals with close contact to a person with pertussis.
- Administration of postexposure therapy to asymptomatic contacts of the infected patient within 21 days of onset of cough can prevent symptomatic infection.[1]
- The recommended antimicrobial agents for treatment or chemoprophylaxis of pertussis are azithromycin, clarithromycin and erythromycin. Trimethoprim-sulfamethoxasole can also be used.[1]
Infants
Age ≥1 Month
- Erythromycin, clarithromycin, and azithromycin are preferred for the post exposure prophylaxis of pertussis in persons ≥1 month of age.[1]
- For persons ≥2 months of age, an alternative to macrolides is trimethoprim-sulfamethoxazole.[1]
Age <1 Month
- For infants <1 month of age, azithromycin is preferred for post exposure prophylaxis and treatment because azithromycin has not been associated with infantile hypertrophic pyloric stenosis (IHPS), whereas erythromycin has.[1]